DAFNA Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

DAFNA Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.32M	Buy	164,285 +25,000	+18%	+$215K	0.25%	60
2026 Q1	$1.12M	Sell	139,285 -50,780	-27%	-$487K	0.25%	57
2025 Q4	$2.21M	Buy	190,065 +49,565	+35%	+$482K	0.51%	47
2025 Q3	$1.41M	Buy	+140,500	New	+$2.02M	0.35%	53
2025 Q2	–	Sell	-95,290	Closed	-$1.2M	–	82
2025 Q1	$1.2M	Buy	95,290 +6,500	+7%	+$78.2K	0.34%	51
2024 Q4	$937K	Sell	88,790 -59,504	-40%	-$833K	0.24%	59
2024 Q3	$2.15M	Sell	148,294 -90,900	-38%	-$1.08M	0.51%	45
2024 Q2	$2.04M	Hold	239,194	–	–	0.49%	43
2024 Q1	$2.44M	Sell	239,194 -71,975	-23%	-$537K	0.56%	41
2023 Q4	$1.71M	Buy	+311,169	New	+$1.36M	0.41%	47

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

DAFNA Capital Management's SPRY Position: Q2 2026 in Review

DAFNA Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 18% in Q2 2026, buying an estimated $215K and bringing the position to 164,285 shares worth $1.32M. The position accounts for 0.25% of the portfolio, ranked #60.

DAFNA Capital Management first reported a position in SPRY in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.44M in Q1 2024. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

DAFNA Capital Management held 164,285 shares of ARS Pharmaceuticals worth $1.32M as of Q2 2026.
DAFNA Capital Management bought 25,000 ARS Pharmaceuticals shares in Q2 2026, an estimated $215K.
ARS Pharmaceuticals made up 0.25% of DAFNA Capital Management's portfolio in Q2 2026, its #60 holding.
DAFNA Capital Management first reported a position in ARS Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
DAFNA Capital Management's ARS Pharmaceuticals position peaked at $2.44M in Q1 2024.
208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.